A phase 3 pivotal study evaluating SM-020 for the treatment of seborrheic keratosis
Latest Information Update: 27 Feb 2024
At a glance
- Drugs SM-020 (Primary)
- Indications Seborrhoeic keratosis
- Focus Registrational; Therapeutic Use
- Sponsors DermBiont
Most Recent Events
- 22 Feb 2024 According to a DermBiont media release, positive results from Phase 2b clinical trial will support End of Phase 2 Meeting with FDA submission package to the FDA in Q4 2024 and ultimate regulatory alignment for designing DermBionts Phase 3 pivotal trial.
- 30 Jun 2022 New trial record
- 23 Jun 2022 According to a DermBiont media release, this trial plans to initiate as early as Q1 2024.